medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-13-54-56medsovet-1986Research ArticleЭНДОМЕТРИОЗСОВРЕМЕННЫЕ АСПЕКТЫ ЛЕЧЕНИЯ ЭНДОМЕТРИОЗА. ПРИМЕНЕНИЕ ДИЕНОГЕСТАMODERN ASPECTS OF ENDOMETRIOSIS TREATMENT. USE OF DIENOGESTХилькевичЕ. Г.KhilkevichE. G.

д.м.н.,

Москва

MD,

Moscow

ЛисицынаО. И.LisitsynaO. I.

Москва

Moscow

Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова Минздрава РоссииРоссияResearch Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of RussiaRussian Federation2017081020170135456Copyright © Хилькевич Е.Г., Лисицына О.И., 20172017Хилькевич Е.Г., Лисицына О.И.Khilkevich E.G., Lisitsyna O.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1986

Диеногест – высокоэффективное средство для лечения основных болевых симптомов эндометриоза (хронической тазовой боли, диспареунии и дисменореи) и профилактики рецидива заболевания с высоким профилем безопасности и хорошей переносимостью, что позволяет назначать его с целью долгосрочной терапии заболевания. В пользу выбора именно указанного прогестагена свидетельствуют новейшие данные, отражающие всестороннее воздействие на различные звенья патогенеза заболевания.

Dienogest is a highly effective drug for treating the major pain symptoms of endometriosis (chronic pelvic pain, dyspareunia and dysmenorrhea) and preventing a relapse with a high safety profile and good tolerability allowing to indicate it for longterm treatment of the disease. The latest data reflecting the full impact on the various links of the pathogenesis disease testify in favour of the choice of the specified progestagen.

эндометриоздиеногестВизаннаendometriosisdienogestVizanneReferencesBegum T, Chowdhury SR. Aetiology and pathogenesis of endometriosis – a review. Mymensingh Med. J., 2013, 22(1): 218–21.Begum T, Chowdhury SR. Aetiology and pathogenesis of endometriosis – a review. Mymensingh Med. J., 2013, 22(1): 218–21.Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis, Fertility and Sterility, 2012, 98(3): 511–519.Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis, Fertility and Sterility, 2012, 98(3): 511–519.Giudice L, Kao L. Endometriosis. Lancet, 2004, 364(9447): 1789–99.Giudice L, Kao L. Endometriosis. Lancet, 2004, 364(9447): 1789–99.Eskenazi B, Warner ML. Epidemiology of endometriosis. Obs. Gynecol Clin North Am., 1997, 24(2): 235–58.Eskenazi B, Warner ML. Epidemiology of endometriosis. Obs. Gynecol Clin North Am., 1997, 24(2): 235–58.The Practice Committee of the American Society of Reproductive Medicine, Treatment of pelvic pain associated with endometriosis: A committee opinion, Fertil. Steril., 2014, 101(4): 927–935.The Practice Committee of the American Society of Reproductive Medicine, Treatment of pelvic pain associated with endometriosis: A committee opinion, Fertil. Steril., 2014, 101(4): 927–935.Nnoaham KE, Hummelshoj L, Webster P,’Hooghe TD, De Cicco Nardone F, De Cicco Nardone C, Jenkinson C, Kennedy SH, Zondervan KT. Impact of endometriosis on quality of life and work productivity: A multicenter study across ten countries, Fertil. Steril., 2011, 96(2)6 366–373.e8.Nnoaham KE, Hummelshoj L, Webster P,’Hooghe TD, De Cicco Nardone F, De Cicco Nardone C, Jenkinson C, Kennedy SH, Zondervan KT. Impact of endometriosis on quality of life and work productivity: A multicenter study across ten countries, Fertil. Steril., 2011, 96(2)6 366–373.e8.Johnson NP, Hummelshoj L. Consensus on current management of endometriosis. Hum. Reprod., 2013, 28(6): 1552–1568.Johnson NP, Hummelshoj L. Consensus on current management of endometriosis. Hum. Reprod., 2013, 28(6): 1552–1568.Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills., Fertil. Steril., 2017, 107(3): 533–536.Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills., Fertil. Steril., 2017, 107(3): 533–536.Oettel M, Carol W, Elger W, Kaufmann G, Moore C, Romer W, Klinger G, Schneider B, Schroder J, Sobek L, Walter F, Zimmermann H. A 19-norprogestin without 17(alpha)-ethinyl group II: Dienogest from a pharmacodynamic point of view, Drugs of Today, 1995, 31(7): 517–36.Oettel M, Carol W, Elger W, Kaufmann G, Moore C, Romer W, Klinger G, Schneider B, Schroder J, Sobek L, Walter F, Zimmermann H. A 19-norprogestin without 17(alpha)-ethinyl group II: Dienogest from a pharmacodynamic point of view, Drugs of Today, 1995, 31(7): 517–36.Klipping C, Duijkers I, TA F, SF K, Schuett B. Pharmacodynamic study of four oral dosages of dienogest. Fertility and Sterility, 2010, 94(suppl 1, 4): S181, Abstract P-304.Klipping C, Duijkers I, TA F, SF K, Schuett B. Pharmacodynamic study of four oral dosages of dienogest. Fertility and Sterility, 2010, 94(suppl 1, 4): S181, Abstract P-304.Чернуха Г.Е. Современные прогестагены в лечении эндометриоза (обзор международных исследований). Проблемы репродукции, 2012, 4: 68–71.Чернуха Г.Е. Современные прогестагены в лечении эндометриоза (обзор международных исследований). Проблемы репродукции, 2012, 4: 68–71.Yamanaka K, Xu B, Suganuma I, Kusuki I, Mita S, Shimizu Y, Mizuguchi K, Kitawaki J. Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E 2 production in human endometriotic stromal cells in spheroid culture. Fertil. Steril., 2012, 97(2): 477–482.Yamanaka K, Xu B, Suganuma I, Kusuki I, Mita S, Shimizu Y, Mizuguchi K, Kitawaki J. Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E 2 production in human endometriotic stromal cells in spheroid culture. Fertil. Steril., 2012, 97(2): 477–482.Miyashita M, Koga K, Takamura M, Izumi G, Nagai M, Harada M, Hirata T, Hirota Y, Fujii T, Osuga Y. Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis. Gynecol. Endocrinol., 2014, 3590, 9: 1–5.Miyashita M, Koga K, Takamura M, Izumi G, Nagai M, Harada M, Hirata T, Hirota Y, Fujii T, Osuga Y. Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis. Gynecol. Endocrinol., 2014, 3590, 9: 1–5.G R Attia, K Zeitoun, D Edwards, A Johns, B R Carr, and S E. Bulun, Progesterone receptor isoform A but not B is expressed in endometriosis. J. Clin. Endocrinol. Metab., 2000, 85(8): 2897–2902.G R Attia, K Zeitoun, D Edwards, A Johns, B R Carr, and S E. Bulun, Progesterone receptor isoform A but not B is expressed in endometriosis. J. Clin. Endocrinol. Metab., 2000, 85(8): 2897–2902.Hayashi A, Tanabe A, Kawabe S, Hayashi M, Yuguchi H, Yamashita Y, Okuda K, Ohmichi M. Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis. J. Ovarian Res., 2012, 5(1): 31.Hayashi A, Tanabe A, Kawabe S, Hayashi M, Yuguchi H, Yamashita Y, Okuda K, Ohmichi M. Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis. J. Ovarian Res., 2012, 5(1): 31.Grandi G, Mueller MD, Bersinger NA, Facchinetti F, McKinnon BD. The association between progestins, nuclear receptors expression and inflammation in endometrial stromal cells from women with endometriosis. Gynecol. Endocrinol., 2017, 0(0): 1–4.Grandi G, Mueller MD, Bersinger NA, Facchinetti F, McKinnon BD. The association between progestins, nuclear receptors expression and inflammation in endometrial stromal cells from women with endometriosis. Gynecol. Endocrinol., 2017, 0(0): 1–4.Grandi G, Mueller M, Bersinger N, Papadia A, Nirgianakis K, Cagnacci A, McKinnon B. Progestin suppressed inflammation and cell viability of tumor necrosis factor-α-stimulated endometriotic stromal cells. Am. J. Reprod. Immunol., 2016, 76(4): 292–298.Grandi G, Mueller M, Bersinger N, Papadia A, Nirgianakis K, Cagnacci A, McKinnon B. Progestin suppressed inflammation and cell viability of tumor necrosis factor-α-stimulated endometriotic stromal cells. Am. J. Reprod. Immunol., 2016, 76(4): 292–298.Grandi G, Mueller M, Bersinger NA, Cagnacci A, Volpe A, McKinnon B. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflamm. Res., 2016, 65(3): 183–192.Grandi G, Mueller M, Bersinger NA, Cagnacci A, Volpe A, McKinnon B. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflamm. Res., 2016, 65(3): 183–192.Nirgianakis K, Grandi G, McKinnon B, Bersinger N, Cagnacci A, Mueller M. Dienogest mediates midkine suppression in endometriosis. Hum. Reprod., 2016, 31(9): 1981–1986.Nirgianakis K, Grandi G, McKinnon B, Bersinger N, Cagnacci A, Mueller M. Dienogest mediates midkine suppression in endometriosis. Hum. Reprod., 2016, 31(9): 1981–1986.Choi J, Jo M, Lee E, Lee DY, Choi D. Dienogest enhances autophagy induction in endometriotic cells by impairing activation of AKT, ERK1/2, and mTOR. Fertil. Steril., 2015, 104(3): 655–664.Choi J, Jo M, Lee E, Lee DY, Choi D. Dienogest enhances autophagy induction in endometriotic cells by impairing activation of AKT, ERK1/2, and mTOR. Fertil. Steril., 2015, 104(3): 655–664.Saito F, Tashiro H, Yamaguchi M, Honda R, Ohba T, Suzuki A, Katabuchi H. Development of a mouse model for testing therapeutic agents: The anticancer effect of dienogest on endometrial neoplasms. Gynecol. Endocrinol., 2016, 32(5): 403–407.Saito F, Tashiro H, Yamaguchi M, Honda R, Ohba T, Suzuki A, Katabuchi H. Development of a mouse model for testing therapeutic agents: The anticancer effect of dienogest on endometrial neoplasms. Gynecol. Endocrinol., 2016, 32(5): 403–407.Takaesu Y, Nishi H, Kojima J, Sasaki T, Nagamitsu Y, Kato R, Isaka K. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis, J. Obstet. Gynaecol. Res., 2016, 42(9): 1152–1158.Takaesu Y, Nishi H, Kojima J, Sasaki T, Nagamitsu Y, Kato R, Isaka K. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis, J. Obstet. Gynaecol. Res., 2016, 42(9): 1152–1158.Yamanaka A, Hada T, Matsumoto T, Kanno K, Shirane A, Yanai S, Nakajima S, Ebisawa K, Ota Y, Andou M. Effect of dienogest on pain and ovarian endometrioma occurrence after laparoscopic resection of uterosacral ligaments with deep infiltrating endometriosis, Eur. J. Obstet. Gynecol. Reprod. Biol., 2017, 216: 51–55.Yamanaka A, Hada T, Matsumoto T, Kanno K, Shirane A, Yanai S, Nakajima S, Ebisawa K, Ota Y, Andou M. Effect of dienogest on pain and ovarian endometrioma occurrence after laparoscopic resection of uterosacral ligaments with deep infiltrating endometriosis, Eur. J. Obstet. Gynecol. Reprod. Biol., 2017, 216: 51–55.Maiorana A, Incandela D, Parazzini F, Alio W, Mercurio A, Giambanco L, Alio L. Efficacy of dienogest in improving pain in women with endometriosis: a 12-month single-center experience. Arch. Gynecol. Obstet., 2017.Maiorana A, Incandela D, Parazzini F, Alio W, Mercurio A, Giambanco L, Alio L. Efficacy of dienogest in improving pain in women with endometriosis: a 12-month single-center experience. Arch. Gynecol. Obstet., 2017.Park SY, Kim SH, Chae HD, Kim C-H, Kang BM. Efficacy and safety of dienogest in patients with endometriosis: A single-center observational study over 12 months, Clin. Exp. Reprod. Med., 2016, 43(4): 215.Park SY, Kim SH, Chae HD, Kim C-H, Kang BM. Efficacy and safety of dienogest in patients with endometriosis: A single-center observational study over 12 months, Clin. Exp. Reprod. Med., 2016, 43(4): 215.Adachi K, Takahashi K, Nakamura K, Otake A, Sasamoto N, Miyoshi Y, Shioji M, Yamamoto Y, Fujitani M. Postoperative administration of dienogest for suppressing recurrence of disease and relieving pain in subjects with ovarian endometriomas. Gynecol. Endocrinol., 2016, 32(8): 646–649.Adachi K, Takahashi K, Nakamura K, Otake A, Sasamoto N, Miyoshi Y, Shioji M, Yamamoto Y, Fujitani M. Postoperative administration of dienogest for suppressing recurrence of disease and relieving pain in subjects with ovarian endometriomas. Gynecol. Endocrinol., 2016, 32(8): 646–649.Kim SA, Um MJ, Kim HK, Kim SJ, Moon SJ, Jung H. Study of dienogest for dysmenorrhea and pelvic pain associated with endometriosis. Obstet. Gynecol. Sci., 2016, 59(6): 506–511.Kim SA, Um MJ, Kim HK, Kim SJ, Moon SJ, Jung H. Study of dienogest for dysmenorrhea and pelvic pain associated with endometriosis. Obstet. Gynecol. Sci., 2016, 59(6): 506–511.Доброхотова Ю.Э., Гришин И.Г., Ибрагимова Д.М., Нуруллин Р.Ф. Опыт применения Визанны у пациенток с диагностированным эндометриозом. Проблемы репродукции, 2014, 33–35.Доброхотова Ю.Э., Гришин И.Г., Ибрагимова Д.М., Нуруллин Р.Ф. Опыт применения Визанны у пациенток с диагностированным эндометриозом. Проблемы репродукции, 2014, 33–35.Ярмолинская М.И., Беженарь В.Ф. Опыт применения диеногеста в комбинированном лечении генитального эндометриоза. Фарматека, 2013, 3: 48–51.Ярмолинская М.И., Беженарь В.Ф. Опыт применения диеногеста в комбинированном лечении генитального эндометриоза. Фарматека, 2013, 3: 48–51.García Uranga-Romano A, Hernández-Valencia J, Zárate M, Basavilvazo-Rodríguez MA. Dienogest usefulness in pelvic pain due to endometriosis. A meta-analysis of its effectiveness. Rev Med Inst Mex Seguro Soc., 2017, 55(4) 452–455.García Uranga-Romano A, Hernández-Valencia J, Zárate M, Basavilvazo-Rodríguez MA. Dienogest usefulness in pelvic pain due to endometriosis. A meta-analysis of its effectiveness. Rev Med Inst Mex Seguro Soc., 2017, 55(4) 452–455.

The authors declare that there are no conflicts of interest present.